Holen Sie sich die Stockscreener-App
2.66
0.75%
-0.02
Vorhandelsmarkt:
2.66
Schlusskurs vom Vortag:
$2.68
Offen:
$2.68
24-Stunden-Volumen:
18,462
Relative Volume:
0.34
Marktkapitalisierung:
$7.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.56M
KGV:
-0.2734
EPS:
-9.7281
Netto-Cashflow:
$-12.24M
1W Leistung:
-6.50%
1M Leistung:
-3.97%
6M Leistung:
-68.71%
1J Leistung:
-56.78%
1-Tages-Spanne:
$2.62
$2.7215
1-Wochen-Bereich:
$2.50
$2.935
52-Wochen-Spanne:
$1.76
$19.63
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Firmenname
Processa Pharmaceuticals Inc
Sektor
Branche
Telefon
443-776-3133
Adresse
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
2.66 | 7.29M | 0 | -13.56M | -12.24M | -9.7281 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-25 | Eingeleitet | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Aktie (PCSA) Neueste Nachrichten
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Ng George K - Moomoo
Insider Buying: Russell Skibsted Acquires Additional Shares of P - GuruFocus
Processa Pharmaceuticals CFO Skibsted buys $5,891 in stock By Investing.com - Investing.com Australia
Processa Pharmaceuticals CFO Skibsted buys $5,891 in stock - Investing.com
Processa Pharma strategy chief Lin buys $4,064 in stock By Investing.com - Investing.com India
Processa Pharma strategy chief Lin buys $4,064 in stock - Investing.com
Processa (PCSA) CAO Wendy Guy buys 1,748 shares in open-market trade - Stock Titan
Processa Pharmaceuticals president David Young buys $4,589 in shares By Investing.com - Investing.com Australia
Processa Pharmaceuticals CEO George Ng buys $5,471 in company stock By Investing.com - Investing.com India
Processa Pharmaceuticals president David Young buys $4,589 in shares - Investing.com
Processa Pharmaceuticals CEO George Ng buys $5,471 in company stock - Investing.com
David Young of Processa (NASDAQ: PCSA) buys 1,706 shares at $2.69 - Stock Titan
Processa Pharmaceuticals (PCSA) CFO adds 2,190 shares in open-market buy - Stock Titan
Processa (NASDAQ: PCSA) CEO George Ng buys 2,034 shares in open-market trade - Stock Titan
Processa (PCSA) strategy chief buys 1,511 shares at $2.69 - Stock Titan
Processa (NASDAQ: PCSA) CDO adds 1,986 shares in open-market buy - Stock Titan
2025 Executive Compensation, Ownership, and Governance Overview for Heatwurx, Inc. (Now Based in Vero Beach, FL) - Minichart
Processa Pharmaceuticals | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Ng George Kmoomoo - Moomoo
Processa Pharmaceuticals Announces Transition of Chief Development Officer - TipRanks
Processa Pharmaceuticals CEO George Ng buys $5,414 in stock By Investing.com - Investing.com Canada
Processa Pharmaceuticals (NASDAQ: PCSA) details governance, pay and ownership in 10-K/A - Stock Titan
Chief development leader at Processa (NASDAQ: PCSA) moves to part-time post - Stock Titan
Processa Pharmaceuticals CEO George Ng buys $5,414 in stock - Investing.com
Processa (NASDAQ: PCSA) CEO adds 1,843 shares in open-market buy - Stock Titan
Processa Pharmaceuticals (PCSA) CEO buys 2,136 shares in open market - Stock Titan
PCSA stock rallies 10% after hours—here’s why - MSN
Processa Pharmaceuticals Inc. (PCSA) Share Price Today | Processa Pharmaceuticals (PCSA) Live NSE/BSE - Value Research
PCSA Stock Price, Quote & Chart | PROCESSA PHARMACEUTICALS INC (NASDAQ:PCSA) - ChartMill
Is Processa Pharmaceuticals (PCSA) stock testing important levels (Pressure Mounts) 2026-04-20Wall Street Picks - Xã Thanh Hà
Processa Pharma director Young buys shares worth $4,588 By Investing.com - Investing.com Australia
Lin Patrick, Processa Pharma chief, buys $4,065 in PCSA stock By Investing.com - Investing.com South Africa
Processa Pharma director Young buys shares worth $4,588 - Investing.com
Lin Patrick, Processa Pharma chief, buys $4,065 in PCSA stock - Investing.com
Bigora Sian, chief development officer, buys Processa shares By Investing.com - Investing.com Australia
Processa Pharma CFO Skibsted buys $5892 in PCSA stock By Investing.com - Investing.com Canada
Bigora Sian, chief development officer, buys Processa shares - Investing.com
Processa Pharmaceuticals (NASDAQ: PCSA) R&D chief buys 1,545 shares in open market - Stock Titan
Processa Pharmaceuticals (PCSA) CEO adds 1,843 shares in open-market buy - Stock Titan
Processa (PCSA) strategy chief buys 1,369 shares at $2.97 - Stock Titan
Processa (NASDAQ: PCSA) CAO Wendy Guy buys 1,583 shares in open market - Stock Titan
Processa (PCSA) CDO buys 1,799 company shares in open market - Stock Titan
Processa (NASDAQ: PCSA) CFO adds 1,984 shares in open-market buy - Stock Titan
Institution Moves: Is Processa Pharmaceuticals Inc impacted by rising rates2026 Price Targets & Verified Stock Trade Ideas - baoquankhu1.vn
Market Recap: What are the risks of holding Processa Pharmaceuticals IncMarket Activity Recap & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Finanzdaten der Processa Pharmaceuticals Inc-Aktie (PCSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Processa Pharmaceuticals Inc-Aktie (PCSA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SKIBSTED RUSSELL | Chief Financial Officer |
Apr 30 '26 |
Buy |
2.69 |
2,190 |
5,891 |
6,498 |
| Ng George K | Chief Executive Officer |
Apr 30 '26 |
Buy |
2.69 |
2,034 |
5,471 |
6,013 |
| Lin Patrick | Chief Business - Strategy Off |
Apr 30 '26 |
Buy |
2.69 |
1,511 |
4,065 |
6,236 |
| Guy Wendy | Chief Administrative Officer |
Apr 30 '26 |
Buy |
2.69 |
1,748 |
4,702 |
6,441 |
| Bigora Sian | Chief Development Officer |
Apr 30 '26 |
Buy |
2.69 |
1,986 |
5,342 |
7,496 |
| Young David | Pres. Research & Development |
Apr 15 '26 |
Buy |
2.97 |
1,545 |
4,589 |
12,107 |
| Ng George K | Chief Executive Officer |
Apr 15 '26 |
Buy |
2.97 |
1,843 |
5,474 |
5,492 |
| Lin Patrick | Chief Business - Strategy Off |
Apr 15 '26 |
Buy |
2.97 |
1,369 |
4,066 |
4,725 |
| Guy Wendy | Chief Administrative Officer |
Apr 15 '26 |
Buy |
2.97 |
1,583 |
4,702 |
4,693 |
| Bigora Sian | Chief Development Officer |
Apr 15 '26 |
Buy |
2.97 |
1,799 |
5,343 |
5,510 |
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):